Molecular actions of the novel histone deacetylase inhibitor CG-1521 in models of inflammatory breast cancer

Author

Namita Chatterjee, University at Albany, State University of New YorkFollow

Date of Award

1-1-2014

Language

English

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

College/School/Department

Department of Biomedical Sciences

Content Description

1 online resource (xvii, 227 pages) : color illustrations.

Dissertation/Thesis Chair

Martin P Tenniswood

Committee Members

JoEllen Welsh, Douglas S Conklin, Thomas J Begley, Jason I Herschkowitz

Keywords

Epigenetic Therapy, Histone Deacetylase, Histone Deacetylase Inhibitor, Inflammatory Breast Cancer, Breast, Histone deacetylase, Enzyme inhibitors, Carcinogenesis

Subject Categories

Biology | Molecular Biology | Oncology

Abstract

Inflammatory breast cancer (IBC) is a rare and particularly lethal form of breast cancer. Despite aggressive therapeutic approaches, the 5-year survival rate is only 34%. As this disease is severely understudied, we have investigated the therapeutic potential of the novel hydroxamic acid-derived histone deacetylase inhibitor (HDACi), CG-1521 in comparison to a structurally similar compound, Trichostatin A (TSA) in two IBC cell lines: SUM149PT and SUM190PT. In these cells, CG-1521 and TSA induce dose- and time-dependent induction of cell cycle arrest and apoptosis regardless of the presence of 17β-estradiol (E2). Interestingly, the cell lines have considerably different sensitivities to these treatments despite their common disease origin.

Recommended Citation

Chatterjee, Namita, "Molecular actions of the novel histone deacetylase inhibitor CG-1521 in models of inflammatory breast cancer" (2014). Legacy Theses & Dissertations (2009 - 2024). 1101.
https://scholarsarchive.library.albany.edu/legacy-etd/1101